Did You Know...
...that in 1800 ether was first used by partyers as a fun diversion? Sniffing the gas led to hilarious and raucous laughter as people watched each other become more and more intoxicated and silly. Several doctors independently realized the value ether would have to anesthetize surgery patients. Of those who claimed rights to the "discovery," none had a happy ending. One had a seizure and died defending his rights. Another spent his life in an asylum because he had been denied acclaim. A third became addicted to chloroform and, in a New York City jail, he soaked a cloth in the drug, severed an artery and bled to death.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 6976981 | Osmotic delivery system with membrane plug retention mechanism An osmotic delivery system has a membrane plug retention mechanism which can also be used to control the delivery rate of a beneficial agent from the osmotic delivery system. The osmotic delivery device includes an implant capsule containing a beneficial agent and a... | 12/20/2005 |
| 6962927 | Method for potentiating primary drugs in treating multidrug resistant disease The specification discloses a method for enhancing the inhibiting action of drugs against multidrug resistant cells, apparently by reversing or inhibiting the glycoprotein “pumps” associated with such cells. ... | 11/08/2005 |
| 6911454 | Method for potentiating primary drugs in treating multidrug resistant disease The specification discloses a method for enhancing the inhibiting action of drugs against multidrug resistant cells, apparently by reversing or inhibiting the glycoprotein “pumps” associated with such cells. ... | 06/28/2005 |
| 6896897 | Flexible applicator for applying oil-in-water emulsion with improved stability A flexible applicator for applying an oil-in-water emulsion comprises: (1) an allantoin-containing oil-in-water emulsion; and (2) a flexible element that adsorbs or absorbs the emulsion such that the emulsion is applied to the skin of a patient on whom the flexible ... | 05/24/2005 |
| 6894056 | Method for diagnosing and alleviating the symptoms of chronic fatigue syndrome A method for alleviating chronic fatigue syndrome with the administration of antiviral agents. Based on clinical tests, chronic fatigue syndrome is a persistent herpes virus infection including incomplete virus multiplication and thus administration of antiviral age... | 05/17/2005 |
| 6894068 | Substituted benzimidazoles as non-nucleoside inhibitors of reverse transcriptase The present invention provides compositions and methods for the treatment of HIV infection. In particular, the present invention provides non-nucleoside inhibitors of reverse transcriptase (RT), as well as methods to treat HIV infection using these non-nucleoside in... | 05/17/2005 |
| 6887879 | Pharmaceutical combination of antiviral agents In accordance with the present invention there is provided a pharmaceutical combination useful for the treatment of viral infections comprising a at least one antiviral active compound of formula (1): and at least one ... | 05/03/2005 |
| 6881748 | Drug targeting A bioreductive conjugate comprises a bioreductive moiety with at least one therapeutic agent linked thereto and physiologically acceptable derivatives thereof. The bioreductive moiety incorporates an aromatic ring substituted with a nitro group and the conjugate is ... | 04/19/2005 |
| 6867178 | Calorically dense nutritional composition An enteral composition and method for providing nutrition to metabolically stressed patients. The enteral composition has an energy density of about 1.4 to 1.8 kcal/ml. The enteral composition includes a protein source providing 15% to 20% of the energy of the compo... | 03/15/2005 |
| 6864274 | Allantoin-containing skin cream An allantoin-containing skin cream composition can comprise allantoin and at least one anionic or nonionic emulsifier that is substantially hydrophilic and is soluble in water. The pH of the composition is in a range of from about 3.0 to about 6.0; preferably, the p... | 03/08/2005 |
| 6861441 | Use of EP4 receptor ligands in the treatment of neuropathic pain and colon cancer The present invention relates to the use of an EP4 receptor ligand in the manufacture of a medicament for use in the treatment of neuropathic pain, colon cancer, migraine, and for increasing the latency of HIV infection. ... | 03/01/2005 |
| 6849595 | Calorically dense nutritional composition The present invention provides an enteral composition and method for providing nutrition to metabolically stressed patients. Pursuant to the present invention, the enteral composition has an increased caloric density of approximately 1.4 to 1.8 kcal/mL. The enteral ... | 02/01/2005 |
| 6844359 | Substituted imides Novel imides are inhibitors of tumor necrosis factor alpha and can be used to combat cachexia, endotoxic shock, and retrovirus replication. A typical embodiment is (R)-2-Phthalimido-3-(3′,4′-dimethoxyphenyl)propane. ... | 01/18/2005 |
| 6838477 | Lactacystin analogs Described herein are compounds related to lactacystin and lactacystin β-lactone, pharmaceutical compositions containing the compounds, and methods of use. ... | 01/04/2005 |
| 6825177 | Aryl phosphate derivatives of d4T with potent anti-viral activity Methods for increasing the elimination half-life of key metabolites such as d4T by administering an aryl phosphate derivative of d4T having an electron withdrawing substituent on the aryl group and an amino acid substituent on the phosphate group are described. A pr... | 11/30/2004 |
| 6815461 | Method of inhibiting retroviral integrase Disclosed is a method of inhibiting retroviral integrase in a subject in need of such treatment. The method comprises administering to the subject an effective retroviral integrase inhibiting amount of a bis-benzimidazole compound such as bis[5-amidino-2-benzimidazo... | 11/09/2004 |
| 6803375 | Non-peptide inhibition of T-lymphocyte activation and therapies related thereto Compounds, preparations and methods for immunosuppressive treatment of autoimmune disorders, graft rejection and/or graft/host disease. Therapeutically effective amounts of certain substituted triarylmethane compounds, such as 1-[(2-chlorophenyl)diphenylmethyl]-1H-p... | 10/12/2004 |
| 6797729 | Therapeutic glutamine and N-actyl-cysteine composition Compositions comprising glutamine in combination with other ingredients such as N-acetyl-cysteine are disclosed. Such compositions can be administered to treat patients with certain conditions of the body. ... | 09/28/2004 |
| 6797255 | Methods and compositions for enhancing magnetic resonance imaging Substantially nontoxic manganese complexes of compounds of the formula: wherein n=0, 1 or 2, R1 and R2 are hydrogen or alkyl groups of 1 to 4 carbon atoms, and R3 and R4 are hy... | 09/28/2004 |
| 6790451 | Cosmetic material A cosmetic material comprising as essential cosmetic constituents (A) a silicone-branched silicone compound and (B) a silicone-branched polyether-modified silicone compound. ... | 09/14/2004 |
| 6787527 | Methods of preventing and treating HIV infection The present invention relates, in general, to a method of preventing or treating human immunodeficiency virus (HIV) infection, and in particular, to a method of preventing or treating HIV infection using a cobalamin. The invention further relates to compositions sui... | 09/07/2004 |
| 6777411 | Fungicide mixtures based on pyride amides and morpholine derivatives or piperidine derivatives Fungicidal mixtures comprising as active components a) an amide compound of the formula I A—CO—NR1R2 I in which A is an aryl group or an aromatic or non-aromatic, 5- or 6-membered hetero... | 08/17/2004 |
| 6774123 | Methods and compositions for inactivating viruses Methods and compositions for selectively inactivating viruses in biological compositions, including contacting the composition with an organic solvent and an ethyleneimine oligomer inactivating agent, are disclosed. ... | 08/10/2004 |
| 6765020 | Drugs for prevention and treatment of diseases caused by abnormalities in cartilage tissues Drug or foods and drink for prevention or treatment of diseases caused by abnormalities in cartilage tissues in which said drugs or foods and drinks have omega-9 unsaturated fatty acid as an active ingredient. ... | 07/20/2004 |
| 6765007 | High-content famciclovir tablets A pharmaceutical tablet wherein famciclovir is the active ingredient and wherein the percentage of famciclovir by weight in the tablet is 85% or greater. ... | 07/20/2004 |
| 6737041 | Non-ozone depleting vapocoolants Chemical compositions are provided, for use as topical anesthetics or skin refrigerants. These compositions do not cause the depletion of the stratospheric ozone layer and are non-toxic, non-carcinogenic and less flammable than ethyl chloride. Also these chemical co... | 05/18/2004 |
| 6737082 | Pharmaceutical oral preparation of a compound having an antifungic activity, and preparation method It comprises a compound having antifungal activity as active principle, an inert core and a coating including said active principle, and is characterized in that said inert core has a particle size comprised between 50 and 600 μm, and in that said coating comprises... | 05/18/2004 |
| 6733767 | Liquid polymeric compositions for controlled release of bioactive substances Controlled release of hydrophobic bioactive substances in vivo over an extended time period and without “bursts” of drug release is achieved using a liquid polymeric composition including a polymer such as poly(lactide-co-glycolide) copolymer in a mixture of hyd... | 05/11/2004 |
| 6730679 | Pharmaceutical formulations Pharmaceutical formulations containing HIV protease inhibitors, specifically including 3S-[3R*(1R*,2S*)]-[3-[[(4-aminophenyl)sulphonyl](2-methylpropyl)-amino]-2-hydroxy-1-phenylmethyl)propyl]carbamic acid, tetrahydro-3-furanyl ester (alternatively known as VX 478 or... | 05/04/2004 |
| 6727240 | Methods for preventing HIV-1 or HIV-2 infection A method of preventing HIV-1 or HIV-2 infection by administering to a human a pharmaceutically effective anti-HIV-1 or anti-HIV-2 amount of a tin or silicon protoporphyrin IX or tin or silicon mesoporphyrin IX, or a pharmaceutically acceptable salt thereof. ... | 04/27/2004 |
| 6726934 | Micro-particulate and nano-particulate polymeric delivery system The present invention provides a method of making particles useful in drug delivery, comprising the steps of: contacting polyanionic polymers with cations in a stirred reactor so that polyanions and the cations react to form particles. ... | 04/27/2004 |
| 6726923 | Apparatus and methods for preventing or treating failure of hemodialysis vascular access and other vascular grafts This invention is a prosthetic device generally placed on the outside surface of the vessel or graft which then elutes antiproliferative drugs or agents from a drug-eluting matrix material. Methods of perivascular antiproliferative drug administration also are discl... | 04/27/2004 |
| 6727280 | Method for treating colorectal carcinoma using a taxane/tocopherol formulation The present invention provides methods for administering a taxane composition for the treatment of cancer. In one aspect, the compositions are not diluted prior to administration. Some embodiments provide methods for administering a taxane as a bolus injection or an... | 04/27/2004 |
| 6720314 | Use of a vital dye for facilitating surgical procedures for cataract extraction Methods for performing a capsulorhexis are disclosed wherein a dye is used to stain a lens capsule of an eye. The dye is capable of staining tissue without diffusing through the tissue. Compositions including dyes that are useful in the methods are also disclosed. | 04/13/2004 |
| 6716412 | Methods of ultrasound treatment using gas or gaseous precursor-filled compositions The present invention describes, among other things, the surprising discovery that gaseous precursor filled compositions are profoundly more effective as acoustically active contrast agents when they are thermally preactivated to temperatures at or above the boiling... | 04/06/2004 |
| 6716411 | Method for finding nucleotide synthesis inhibitors having fewer side effects The invention relates to a method for finding nucleotide synthesis inhibitors which have a better therapeutic window. An efficacious dose of a nucleotide synthesis inhibitor is administered to a mammal. The concentration of the nucleotide synthesis inhibitor in the ... | 04/06/2004 |
| 6713501 | Supplement for dialysis patients Use of a tablet diet supplement for administration to a dialysis patient comprising a mixture of L-histidine, L-isoleucine, L-leucine, L-lysine, L-methionine, L-phenylalanine, L-threonine, L-tryptophan, L-tyrosine and L-valine, for preventing and/or correcting hypoa... | 03/30/2004 |
| 6713083 | Coated bioabsorbable beads for wound treatment The invention provides a material for use in a wound dressing or wound implant, the material comprising a plurality of beads, wherein each bead comprises a porous core of a first bioabsorbable material and a substantially non-porous layer of a second bioabsorbable m... | 03/30/2004 |
| 6710077 | Use of thiocarboxanilide derivatives for the preparation of a medicament for preventing the transmission of HIV to uninfected cells and contraceptive compositions comprising the said derivatives Method for preventing or inhibiting the transmission of HIV to susceptible uninfected cells by administering to the HIV, to cells infected with HIV, and/or to the uninfected cells, an effective amount of a compound of formula (I), wherein X is O or S, prior to the H... | 03/23/2004 |
| 6709678 | Easy to swallow oral medicament composition An oral composition which is adapted to be dispersed in an aqueous carrier substantially immediately prior to administration comprises a multiplicity of particles comprising an active substance, the particles being combined with one or more gelling or swelling agent... | 03/23/2004 |
